Last update:

HIV & AIDS news

HIV & AIDS

Cannabis use disorder is increasing rapidly, especially among older adults and people living with HIV

The new findings underscore the need for universal screening and treatment for the disorder, as well as concerted research to better understand the benefits and risks of cannabis among different populations.

HIV & AIDS

Cutting HIV aid means undercutting US foreign and economic interests. Nigeria shows the human costs

A little over two decades ago, addressing Nigeria's HIV crisis topped U.S. President George W. Bush's priorities. Africa's most populous nation had 3.5 million HIV cases, and the disease threatened to destabilize the region ...

HIV & AIDS

Tackling HIV with machine learning

Hiding behind numerous disguises, HIV has been evading researchers for years, leaving the search for a vaccine as elusive as the virus itself.

HIV & AIDS

US funding cuts have crippled our HIV work. What's being lost?

The Trump administration's cuts to funding for scientific research have left many scientists reeling and very worried. At the National Institutes of Health in the US, which has an annual budget of US$47 billion to support ...

HIV & AIDS

Unexpected hives reaction seen in trial of mRNA vax against HIV

A safety analysis of mRNA vaccination in a phase 1, randomized, open-label clinical trial evaluated the safety and tolerability of three investigational HIV-1 trimer mRNA vaccines. The study vaccines were found to be generally ...

HIV & AIDS

How a potential HIV cure may affect transmission

A mathematical modeling study coordinated by UMC Utrecht has shown that sustained HIV remission (without rebound) or HIV eradication cure scenarios could consistently reduce new HIV infections among men who have sex with ...

HIV & AIDS

Worm eradication: A surprising ally in the fight against HIV

Researchers from the Munich Tropical Institute, the Tanzanian NIMR-MMRC, DZIF, together with colleagues from Bonn, have discovered a risk factor for HIV infection that has received little attention to date. In an earlier ...

HIV & AIDS

What we can learn from HIV to help end this pandemic

COVID-19 isn't the first time the world has had to deal with a global pandemic—and it won't be the last. But lessons learned from previous disease outbreaks, such as HIV/AIDS, play a key role in providing the tools and ...

Medical research

Q & A: Unravelling the complexity of HIV/AIDS

Dr. Josien de Klerk, Associate professor in Global Public Health at Leiden University College The Hague recently published some of her work on HIV/AIDS. In collaboration with a team of interdisciplinary researchers from the ...

HIV & AIDS

FDA approves first condom designed for anal sex

The first condom specifically designed to prevent the transmission of HIV and other sexually transmitted infections during anal sex has been approved for sale in the United States, the U.S. Food and Drug Administration says.

Genetics

COVID-19 genetic risk variant protects against HIV

The genetic variants we are born with can increase or decrease our risk of falling seriously ill with COVID-19. The major genetic risk variant for severe COVID-19, one we inherited from Neandertals, is surprisingly common. ...

HIV & AIDS

New 'highly virulent' HIV strain discovered in the Netherlands

Oxford researchers announced Thursday the discovery of a highly virulent strain of HIV that has been lurking in the Netherlands for decades, but because of the effectiveness of modern treatments, is "no cause for alarm."

HIV & AIDS

Tracking cells that host HIV

New research sheds light on the lifespans and location of the cells that are responsible for producing HIV, preventing its eradication. Understanding the cells' dynamics may help scientists develop new ways to reduce their ...

Medications

Promising results of Phase 1 drug trial for HIV patients

A Phase 1 clinical trial conducted by University of Minnesota researchers has demonstrated the safety and efficacy of a novel immunotherapy drug in the treatment of human immunodeficiency virus (HIV). Results of the trial ...

Medications

Long-acting cabotegravir not necessarily cost-effective for PrEP

(HealthDay)—For men who have sex with men and transgender women (MSM/TGW) at very high risk for HIV (VHR), the benefits of long-acting injectable cabotegravir (CAB-LA) in terms of life expectancy do not necessarily justify ...